JP2015514090A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015514090A5 JP2015514090A5 JP2015503464A JP2015503464A JP2015514090A5 JP 2015514090 A5 JP2015514090 A5 JP 2015514090A5 JP 2015503464 A JP2015503464 A JP 2015503464A JP 2015503464 A JP2015503464 A JP 2015503464A JP 2015514090 A5 JP2015514090 A5 JP 2015514090A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- seq
- amino acid
- antibody
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 29
- 238000009472 formulation Methods 0.000 claims 27
- 125000003275 alpha amino acid group Chemical group 0.000 claims 18
- 239000011230 binding agent Substances 0.000 claims 8
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 5
- 229920001213 Polysorbate 20 Polymers 0.000 claims 5
- 239000007979 citrate buffer Substances 0.000 claims 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 5
- 229940068977 polysorbate 20 Drugs 0.000 claims 5
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 claims 4
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 claims 4
- 101710082516 C-X-C chemokine receptor type 5 Proteins 0.000 claims 4
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 claims 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 230000001939 inductive effect Effects 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 102000012220 Member 14 Tumor Necrosis Factor Receptors Human genes 0.000 claims 3
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 3
- 229930006000 Sucrose Natural products 0.000 claims 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 239000007788 liquid Substances 0.000 claims 3
- 239000005720 sucrose Substances 0.000 claims 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 239000002953 phosphate buffered saline Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 241001529453 unidentified herpesvirus Species 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- 102000001708 Protein Isoforms Human genes 0.000 claims 1
- 108010029485 Protein Isoforms Proteins 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 239000003708 ampul Substances 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 229940090047 auto-injector Drugs 0.000 claims 1
- 239000006172 buffering agent Substances 0.000 claims 1
- 239000006227 byproduct Substances 0.000 claims 1
- 239000007857 degradation product Substances 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 239000008176 lyophilized powder Substances 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261615539P | 2012-03-26 | 2012-03-26 | |
| US61/615,539 | 2012-03-26 | ||
| FR1351013 | 2013-02-06 | ||
| FR1351013 | 2013-02-06 | ||
| PCT/US2013/033881 WO2013148686A2 (en) | 2012-03-26 | 2013-03-26 | Stable igg4 binding agent formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017205914A Division JP6820823B2 (ja) | 2012-03-26 | 2017-10-25 | 安定なＩｇＧ４に基づく結合剤の製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015514090A JP2015514090A (ja) | 2015-05-18 |
| JP2015514090A5 true JP2015514090A5 (enExample) | 2016-03-17 |
| JP6265970B2 JP6265970B2 (ja) | 2018-01-24 |
Family
ID=49261390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015503464A Active JP6265970B2 (ja) | 2012-03-26 | 2013-03-26 | 安定なＩｇＧ４に基づく結合剤の製剤 |
Country Status (7)
| Country | Link |
|---|---|
| EP (3) | EP4527855A3 (enExample) |
| JP (1) | JP6265970B2 (enExample) |
| BR (2) | BR112014023952B1 (enExample) |
| CA (3) | CA3204402A1 (enExample) |
| PL (1) | PL2830658T3 (enExample) |
| RU (1) | RU2644214C2 (enExample) |
| WO (1) | WO2013148686A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3297653T (lt) | 2015-05-22 | 2022-01-10 | The Board Of Trustees Of The Leland Stanford Junior University | Postbariatrinės hipoglikemijos gydymas glp-1 antagonistais |
| GB201608323D0 (en) * | 2016-05-12 | 2016-06-29 | Ucb Biopharma Sprl | Pharmaceutical compositions |
| CN107446044B (zh) * | 2016-05-30 | 2021-04-30 | 越海百奥药业(绍兴)有限公司 | 一种纯化抗体的方法及所用缓冲液 |
| TWI760345B (zh) * | 2016-07-05 | 2022-04-11 | 法商賽諾菲公司 | 抗體調配物 |
| KR20220137159A (ko) * | 2016-07-05 | 2022-10-11 | 사노피 | 항체 제형 |
| AU2017358509A1 (en) * | 2016-11-11 | 2019-05-09 | Bayer Aktiengesellschaft | Method for sampling fluid streams for monitoring contaminants in a continuous flow |
| DK3541366T3 (da) * | 2016-11-21 | 2025-03-03 | Amylyx Pharmaceuticals Inc | Bufferformuleringer af exendin (9-39) |
| GB201701194D0 (en) * | 2017-01-24 | 2017-03-08 | Capella Bioscience Ltd | Antigen binding molecules that bind light |
| EP3589318A1 (en) * | 2017-03-01 | 2020-01-08 | MedImmune Limited | Formulations of monoclonal antibodies |
| TW202228779A (zh) * | 2017-03-01 | 2022-08-01 | 英商梅迪繆思有限公司 | 抗rsv單株抗體配製物 |
| GB201708655D0 (en) | 2017-05-31 | 2017-07-12 | Ucb Biopharma Sprl | Cell culture methods |
| US11312781B2 (en) | 2018-01-24 | 2022-04-26 | Capella Bioscience Ltd. | Antigen binding molecules that bind LIGHT |
| JP2024502825A (ja) * | 2020-12-30 | 2024-01-23 | エーマックス バイオ， インコーポレイテッド | 抗体の局所的延長放出 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2966592B2 (ja) * | 1991-07-20 | 1999-10-25 | 萩原 義秀 | 安定化されたヒトモノクローナル抗体製剤 |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| WO2003068259A1 (fr) * | 2002-02-14 | 2003-08-21 | Chugai Seiyaku Kabushiki Kaisha | Produits pharmaceutiques en solution contenant des anticorps |
| ZA200506159B (en) * | 2003-02-10 | 2006-10-25 | Elan Pharm Inc | Immunoglobulin formulation and method of preparation thereof |
| EP1532983A1 (en) * | 2003-11-18 | 2005-05-25 | ZLB Bioplasma AG | Immunoglobulin preparations having increased stability |
| TW200621282A (en) * | 2004-08-13 | 2006-07-01 | Wyeth Corp | Stabilizing formulations |
| US20060148009A1 (en) | 2004-10-12 | 2006-07-06 | Xencor, Inc. | Prediction and assessment of immunogenicity |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| WO2007074880A1 (ja) * | 2005-12-28 | 2007-07-05 | Chugai Seiyaku Kabushiki Kaisha | 抗体含有安定化製剤 |
| GEP20125628B (en) * | 2006-04-21 | 2012-09-10 | Novartis Ag | Pharmaceutical compositions containing antagonist anti-cd40 antibody |
| EP2484696B1 (en) | 2006-08-28 | 2017-08-16 | Kyowa Hakko Kirin Co., Ltd. | Antagonistic hLIGHT-specific human monoclonal antibodies |
| CN101553504A (zh) * | 2006-12-11 | 2009-10-07 | 豪夫迈·罗氏有限公司 | Aβ抗体胃肠外制剂 |
| US20090208492A1 (en) * | 2007-06-14 | 2009-08-20 | Elan Pharmaceuticals, Inc. | Lyophilized Immunoglobulin Formulations and Methods of Preparation |
| SI2195023T1 (en) * | 2007-08-29 | 2018-07-31 | Sanofi | Humanized anti-CXCR5 antibodies, their derivatives and their uses |
| JP6024025B2 (ja) * | 2011-05-02 | 2016-11-09 | イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． | 少容量投与用のアロタイプ選択抗体の限外濾過濃縮 |
-
2013
- 2013-03-26 CA CA3204402A patent/CA3204402A1/en active Pending
- 2013-03-26 EP EP25150972.5A patent/EP4527855A3/en active Pending
- 2013-03-26 CA CA3123252A patent/CA3123252C/en active Active
- 2013-03-26 EP EP13714505.8A patent/EP2830658B1/en active Active
- 2013-03-26 EP EP18190556.3A patent/EP3431104A1/en active Pending
- 2013-03-26 BR BR112014023952-5A patent/BR112014023952B1/pt active IP Right Grant
- 2013-03-26 CA CA2868401A patent/CA2868401C/en active Active
- 2013-03-26 RU RU2014142990A patent/RU2644214C2/ru not_active IP Right Cessation
- 2013-03-26 PL PL13714505T patent/PL2830658T3/pl unknown
- 2013-03-26 WO PCT/US2013/033881 patent/WO2013148686A2/en not_active Ceased
- 2013-03-26 BR BR122019026701-4A patent/BR122019026701B1/pt active IP Right Grant
- 2013-03-26 JP JP2015503464A patent/JP6265970B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015514090A5 (enExample) | ||
| RU2014142990A (ru) | Стабильные препараты связывающего средства на основе igg4 | |
| KR102642385B1 (ko) | 표적화된 키메라 단백질 및 이의 용도 | |
| ES2959257T3 (es) | Composición farmacéutica que comprende construcciones de anticuerpo biespecífico | |
| AU2017287743B2 (en) | Stable liquid pharmaceutical preparation | |
| JP2024012308A (ja) | 抗ｌａｇ－３抗体の投薬量レジメンおよびその使用 | |
| IL274846B2 (en) | Formulation for anti-alpha 4 antibody in cell 7 | |
| JP2013543505A5 (enExample) | ||
| HRP20251036T1 (hr) | Stabilna formulacija antitijela | |
| ES2769123T3 (es) | Anticuerpos de quimiocinas PAN ELR+ CXC | |
| ES2783448T3 (es) | Métodos de tratamiento del lupus eritematoso sistémico utilizando un anticuerpo de dominio dirigido contra CD28 | |
| JP2018502060A5 (enExample) | ||
| JP2016535020A5 (enExample) | ||
| RU2016119755A (ru) | Стабильные водные составы на основе антител | |
| JP2015521593A5 (enExample) | ||
| JP2016537340A5 (enExample) | ||
| FI3209681T3 (fi) | Peptidivariantteja käsittäviä farmaseuttisia koostumuksia ja niiden käyttömenetelmiä | |
| CN106659785B (zh) | 包含gm-csf中和化合物的液体制剂 | |
| JP2017536414A5 (enExample) | ||
| KR20130118879A (ko) | 항―인터류킨―４ 수용체（ｉｌ－４ｒ） 항체를 함유하는 안정화된 제형 | |
| RU2019102943A (ru) | Составы на основе антитела | |
| US11141479B2 (en) | Stable anti-OSMR antibody formulation | |
| CN102791293A (zh) | 肝靶向分子 | |
| KR20220011727A (ko) | 항-angptl3 항체를 포함하는 안정화된 제형 | |
| KR102885113B1 (ko) | 항-rsv 항체의 제제 및 그의 사용 방법 |